Hemagglutinating antibody responses of Lewis-Wistar and Sprague-Dawley rats to graded doses of type-specific pneumococcal polysaccharide were measured. Rats given a small dose (0.2 to 50 ,ug) of type 1 or 8 polysaccharide intraperitoneally developed type-specific hemagglutinating antibody. Rats given larger doses of polysaccharide (-200 ,ug) did not develop detectable hemagglutinating antibody, and they were unresponsive to a subsequent injection of a small (and normally antigenic) dose of polysaccharide. There was prolonged antigenemia in rats injected with a large dose of polysaccharide, and the kinetics of antigen clearance in these animals resembled that reported for mice with polysaccharide immunological paralysis. These results indicate that a phenomenon resembling immunological paralysis with type-specific pneumococcal polysaccharides can be produced in rats.
Mice injected with type-specific pneumococcal polysaccharide (specific soluble substance [SSS1) develop demonstrable hemagglutinating antibody (HA) and protective antibody, but only when an optimal (and low) dose of the polysaccharide is administered. They do not develop detectable antibody when a large dose of SSS is injected, and large doses of SSS render them unresponsive to a subsequent injection of a small, and normally immunogenic, dose of the antigen (2, 5, 8) . This phenomenon, which has been termed "immunological paralysis" (5) , has been evaluated very extensively in mice (2, 5, 6, 8) . There is relatively little information on dose-related effects of SSS on antibody development in other animal species, although studies of other species would appear to have some importance in establishing immunological paralysis as a phenomenon of general biological significance. In the present study, we have evaluated the type-specific HA response of rats to SSS. The results indicate that a phenomenon closely resembling immunological paralysis can be produced in rats with type 1 or 8 SSS.
MATERIALS AND METHODS Animals. Young adult male Lewis-Wistar and Sprague-Dawley albino rats weighing 350 to 420 g were used. Blood samples (1.0 ml) were obtained from the tail vein, and serum was stored at -20 C.
Vaccine antigens. Highly purified type 1 and 8 SSS were obtained as dry powders from Robert S. Baker, Eli Lilly and Co., Indianapolis, Ind. The lot numbers of these vaccine antigens are as follows: type 8, 912643F; type 1, 812632. The polysaccharides were dissolved in normal saline and then administered intraperitoneally (i.p.) in a volume of 1.0 ml.
Serological tests. Type-specific antipneumococcal antibody was detected in rat sera by the indirect hemagglutination method of Ammann and Pelger (1) , utilizing human group 0, Rh+ erythrocytes sensitized with SSS in the presence of chromic chloride. Sensitization was carried out at 30 C. In preliminary studies, we found that human group 0 erythrocytes were usually agglutinated non-specifically by normal rat sera diluted 1:8 or less in saline. Agglutination titers of 16 were observed occasionally. After the sera were absorbed with an equal volume of washed, packed human group 0, Rh+ erythrocytes for 1 h at room temperature, they had hemagglutination titers of s4 in most cases, and none had titers >8. The absorption procedure did not reduce the hemagglutination titers of sera from specifically sensitized animals. Therefore, all rat sera were absorbed with an equal volume of human group 0, Rh+ erythrocytes for 1 h before being tested for HA.
Circulating SSS was measured by counterimmunoelectrophoresis using a method described in detail previously (4) . For the present studies the buffer was modified to contain 2.30 g of barbital, 5 .15 g of barbital-sodium, and 1.46 g of sodium chloride per liter. All tests were carried out with type-specific antipneumococcal sera (Statens Seruminstitut, Copenhagen, Denmark). The quantity of SSS in test sera was calculated as the product of the serum antigen titer and the minimum quantity of SSS in saline that could be detected. Titers of SSS were approximated by testing serial twofold dilutions of serum, and more closely spaced dilutions were then tested to determine the end point. and SSS was cleared from the circulation concomitant with the appearance of measurable HA (Fig. 1A) . In no instance did a given sample of serum have positive tests for both antigen and antibody; this incidental observation provided further confirmation of the specificity of the antibody response.
RESULTS
Rats injected with 1,500 ,ug of type 8 SSS had prolonged antigenemia (Fig. 1B) . Virtually identical results to those depicted in Fig. 1B were obtained in rats injected with 1,500 ug of type 1 SSS. Clearance of SSS from the circulation of animals receiving these large doses of SSS was almost exponential during the first 10 days after injection of the antigen. Thereafter, the rate of clearance of the antigen slowed progressively. SSS was still detectable in the circulation 50 days after injection of the antigen, and HA was not demonstrable. In a subsequent experiment, four rats were given 1,500 gg of type 8 SSS, and SSS became undetectable in the sera between 50 and 60 days after injection of the antigen. HA was not demonstrable in the sera of these animals at any time up to 60 days. The animals were given 2 ,ug of type 8 SSS at 60 days after the initial injection of antigen but remained unresponsive, as judged by negative tests for HA in sera taken 1 and 3 weeks later. 
DISCUSSION
There have been only a few studies of doserelated immunological effects of SSS in animals other than mice. There is some evidence that chickens develop demonstrable antibody or immunological paralysis to SSS, depending on the conditions of the immunization procedure (3, 11) . Early studies indicated that SSS was not immunogenic in rabbits, but data obtained more recently suggest that the apparent lack of INFECT. IMMUN.
on September 6, 2017 by guest http://iai.asm.org/ Downloaded from immunogenicity of SSS in rabbits may be due in part to paralysis, resulting from the use of large doses of SSS for immunization (6, 9) . Previous studies in rats appear to be limited to the observation that type 1 SSS is immunogenic when given by the oral route (10) and a conflicting report that type 1 SSS administered i.p. or subcutaneously is not immunogenic (7) . Since the purity and dose of the polysaccharides used in these earlier studies is unknown, the results cannot be compared with those of the present study.
Our results indicate that type 1 or 8 SSS is antigenic in rats when the dose of SSS is carefully selected. When large doses of SSS (200 to 1,500 ,ug) are used, circulating HA is not demonstrable, and the animals remain apparently unresponsive to subsequent challenge with a low dose of SSS. This effect is type specific; animals injected with a large dose of type 8 SSS continue to respond normally to the injection of a small dose of another type of SSS. This pattern of immunological response to SSS closely resembles the HA and protective antibody responses of mice to these antigens and suggests that SSS can produce immunological paralysis in rats. However, the present findings in rats do not necessarily represent immunological paralysis in the sense employed by Felton et al. (5) in their classic description of this phenomenon, since they defined immunological paralysis in terms of a failure to develop protective antibody. In mice, there is a good correlation between HA responses to SSS and immunity (2, 6), but it is not known whether this is true for rats. The quantities of SSS that elicit, or fail to elicit, a demonstrable HA response in rats appear to be of the same order of magnitude as those used to establish an HA response and immunity or paralysis in mice. For example, we found that rats weighing approximately 400 g had the following HA responses (in terms of micrograms of SSS administered per gram of body weight): <5 x 10-' ug of SSS, no effect; 5 X 10-4 to 10-2 ug of SSS, a demonstrable HA response; and >0.5 ,g of SSS, no HA response. In comparison, representative responses of mice to SSS (6) (in terms of micrograms of SSS administered per gram of body weight) are as follows: <5 x 10-,ug of SSS, no effect; 5 x 10-3 to 10-2 Mg of SSS, immunity; and >1 ug of SSS, paralysis. It is evident from these observations that there is a similarity in the dose-response relationships of rats and mice to SSS.
One feature of immunological paralysis in mice injected with a large quantity of SSS is prolonged antigenemia (8), and we observed a similar phenomenon in rats injected with a large dose of SSS. The kinetics of clearance of SSS in rats with prolonged antigenemia is noteworthy; clearance of SSS is initially exponential, but the rate of antigen elimination slows with time, resulting in prolonged persistence of SSS in the circulation. This pattern of clearance is very similar to the pattern of elimination of SSS in mice (8) . The mechanism responsible for prolonged persistence of SSS in the circulation of mice is not clear. Howard et al. (8) obtained evidence that the persistence of SSS in the circulation was not due to reticuloendothelial blockade by the antigen or to the presence of a poorly phagocytosable fraction of SSS. In keeping with the latter observation, we have found that type 8 SSS in the circulation of rats 50 days after injection of the antigen is identical to the original SSS by Ouchterlony analysis and by chromatography on Sephadex G-200 (J. D. Coonrod, unpublished data). If intact polysaccharide persists for long periods in the circulation or elsewhere, as seems to be the case, it could mask the presence of antibody. Despite numerous studies of the mechanism(s) of immunological paralysis, it is still not certain whether the apparent unresponsiveness of animals to large doses of SSS is due principally to neutralization of antibody by persisting SSS or to central inhibition of antibody formation. Either mechanism might account for the present observations in rats.
